Status:
COMPLETED
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Lead Sponsor:
Edwin Posadas, MD
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lym...
Detailed Description
Cabozantinib (XL184), a multi-targeted tyrosine kinase inhibitor, has demonstrated a powerful clinical phenotype in men with metastatic castrate resistant prostate cancer (mCRPC) both before and after...
Eligibility Criteria
Inclusion
- KEY INCLUSION CRITERIA
- \- mCRPC that includes visceral disease. Visceral metastatic disease is defined as solid organ infiltration that is not bone or lymph node metastases.
- KEY EXCLUSION CRITERIA
- Recent history (\<6 months) of gastrointestinal hemorrhage requiring blood transfusion.
- Tumor involvement in the intestinal lining which the treating physician deems at risk for perforation with rapid tumor response.
Exclusion
Key Trial Info
Start Date :
April 30 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 18 2016
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01834651
Start Date
April 30 2013
End Date
July 18 2016
Last Update
September 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048